Genetic variation of the IL-28B promoter affecting gene expression

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Sugiyama, Masaya ^a,b,d   Tanaka, Yasuhito ^b   Wakita, Takaji ^c   Nakanishi, Makoto ^b   Mizokami, Masashi ^a  

^a NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^b NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^c NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^d JAPAN SOCIETY FOR THE PROMOTION OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; COMPLEMENTARY DNA; LIPOPOLYSACCHARIDE; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; RIBAVIRIN;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ARTICLE; DINUCLEOTIDE REPEAT; EXON; GENE EXPRESSION; GENE FUNCTION; GENE STRUCTURE; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; IL 28A GENE; IL 28B GENE; INTRON; JAPANESE; MOLECULAR CLONING; NUCLEOTIDE SEQUENCE; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM; GENETICS; HEPATITIS C; MOLECULAR GENETICS;

HEPATITIS C VIRUS;

DINUCLEOTIDE REPEATS; GENE EXPRESSION; GENETIC VARIATION; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MOLECULAR SEQUENCE DATA; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RIBAVIRIN;

EID: 80055029005     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026620     Document Type: Article

References (46)

1. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4: 69-77.
2. Sheppard P, Kindsvogel W, Xu W, Henderson K, Schlutsmeyer S, et al. (2003) IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4: 63-68.
3. Mordstein M, Kochs G, Dumoutier L, Renauld JC, Paludan SR, et al. (2008) Interferon-lambda contributes to innate immunity of mice against influenza A virus but not against hepatotropic viruses. PLoS Pathog 4: e1000151.
4. Sommereyns C, Paul S, Staeheli P, Michiels T, (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4: e1000017.
5. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, et al. (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44: 896-906.
6. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, et al. (2006) Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenterology 131: 1887-1898.
7. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, et al. (2007) Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol 81: 7749-7758.
8. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL, (2005) Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 86: 1589-1596.
9. Brand S, Zitzmann K, Dambacher J, Beigel F, Olszak T, et al. (2005) SOCS-1 inhibits expression of the antiviral proteins 2′,5′-OAS and MxA induced by the novel interferon-lambdas IL-28A and IL-29. Biochem Biophys Res Commun 331: 543-548.
10. Robek MD, Boyd BS, Chisari FV, (2005) Lambda interferon inhibits hepatitis B and C virus replication. J Virol 79: 3851-3854.
11. Zhu H, Butera M, Nelson DR, Liu C, (2005) Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2: 80.
12. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461: 399-401.
13. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41: 1100-1104.
14. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41: 1105-1109.
15. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461: 798-801.
16. Tanaka Y, Nishida N, Sugiyama M, Tokunaga K, Mizokami M, (2010) lambda-Interferons and the single nucleotide polymorphisms: A milestone to tailor-made therapy for chronic hepatitis C. Hepatol Res 40: 449-460.
17. Siren J, Pirhonen J, Julkunen I, Matikainen S, (2005) IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. J Immunol 174: 1932-1937.
18. Livak KJ, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.
19. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology pp. 138-1338-1345, 1345 e1331-1337.
20. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, et al. (2010) Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology pp. 139-1577-1585, 1585 e1571-1573.
21. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, et al. (2008) An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 180: 2474-2485.
22. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, et al. (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80: 4501-4509.
23. Contoli M, Message SD, Laza-Stanca V, Edwards MR, Wark PA, et al. (2006) Role of deficient type III interferon-lambda production in asthma exacerbations. Nat Med 12: 1023-1026.
24. Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, et al. (1995) The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med 333: 1171-1175.
25. Monaghan G, Ryan M, Seddon R, Hume R, Burchell B, (1996) Genetic variation in bilirubin UPD-glucuronosyltransferase gene promoter and Gilbert's syndrome. Lancet 347: 578-581.
26. Raijmakers MT, Jansen PL, Steegers EA, Peters WH, (2000) Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 33: 348-351.
27. Sato H, Adachi Y, Koiwai O, (1996) The genetic basis of Gilbert's syndrome. Lancet 347: 557-558.
28. Beutler E, Gelbart T, Demina A, (1998) Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci U S A 95: 8170-8174.
29. Yamamoto K, Sato H, Fujiyama Y, Doida Y, Bamba T, (1998) Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II. Biochim Biophys Acta 1406: 267-273.
30. Gupta E, Lestingi TM, Mick R, Ramirez J, Vokes EE, et al. (1994) Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 54: 3723-3725.
31. Gupta E, Mick R, Ramirez J, Wang X, Lestingi TM, et al. (1997) Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 15: 1502-1510.
32. Rowinsky EK, Grochow LB, Ettinger DS, Sartorius SE, Lubejko BG, et al. (1994) Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res 54: 427-436.
33. Iyer L, King CD, Whitington PF, Green MD, Roy SK, et al. (1998) Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 101: 847-854.
34. Sugatani J, Yamakawa K, Yoshinari K, Machida T, Takagi H, et al. (2002) Identification of a defect in the UGT1A1 gene promoter and its association with hyperbilirubinemia. Biochem Biophys Res Commun 292: 492-497.
35. Iyanagi T, Emi Y, Ikushiro S, (1998) Biochemical and molecular aspects of genetic disorders of bilirubin metabolism. Biochim Biophys Acta 1407: 173-184.
36. Wasserman E, Myara A, Lokiec F, Goldwasser F, Trivin F, et al. (1997) Severe CPT-11 toxicity in patients with Gilbert's syndrome: two case reports. Ann Oncol 8: 1049-1051.
37. Sadee W, Dai Z, (2005) Pharmacogenetics/genomics and personalized medicine. Hum Mol Genet 14 Spec No. 2: R207-214.
38. Modrich P, (1994) Mismatch repair, genetic stability, and cancer. Science 266: 1959-1960.
39. Lengauer C, Kinzler KW, Vogelstein B, (1997) DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci U S A 94: 2545-2550.
40. Lengauer C, Kinzler KW, Vogelstein B, (1997) Genetic instability in colorectal cancers. Nature 386: 623-627.
41. Kim GP, Colangelo LH, Paik S, O'Connell MJ, Kirsch IR, et al. (2007) Predictive value of microsatellite instability-high remains controversial. J Clin Oncol 25: 4857; author reply 4857-4858.
42. Elsaleh H, Joseph D, Grieu F, Zeps N, Spry N, et al. (2000) Association of tumour site and sex with survival benefit from adjuvant chemotherapy in colorectal cancer. Lancet 355: 1745-1750.
43. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, et al. (2000) Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 342: 69-77.
44. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, et al. (2003) Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349: 247-257.
45. Popat S, Hubner R, Houlston RS, (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23: 609-618.
46. Sinicrope FA, Rego RL, Halling KC, Foster N, Sargent DJ, et al. (2006) Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 131: 729-737.